Sector News

Bayer to buy novel drug discovery company for US$2bn

August 13, 2021
Life sciences

Bayer is acquiring biopharmaceutical company Vividion Therapeutics, which uses novel discovery technologies to unlock high value, traditionally “undruggable” targets with precision therapeutics.

According to Jeff Hatfield, CEO of US-based Vividion, about 90% of disease-causing proteins cannot be targeted by current therapies due to the lack of a known addressable binding site.

He said: “Our proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows us to discover previously unknown, or cryptic, functional pockets on the surface of proteins and identify small molecules that selectively bind to those targets.”

Vividion’s proprietary platform can produce a variety of small molecule therapies, yielding highly potent and selective compounds that can address areas of high-unmet medical need. The technology has already proven its applicability pre-clinically in oncology and immune-related disease and could potentially expand into additional indications.

The acquisition will see Bayer gain full rights to Vividion’s discovery platform, which comprises three integrated, synergistic components: a novel chemoproteomic screening technology, an integrated data portal, and a proprietary chemistry library.

However, Vividion will continue to operate as an independent organisation, on an arms-length basis. It will remain accountable for advancing its technology and portfolio while benefiting from Bayer’s experience, infrastructure, and reach as a global pharmaceutical company.

Life science company Bayer expects the acquisition will strengthen its small molecule capabilities and expand its reach into new modalities.

Bayer will pay US$1.5bn upfront, and up to US$500m more in success-based milestone payments.

The transaction is expected to close in Q3 2021.

Stefan Oelrich, President of Bayer’s Pharmaceutical Division, commented: “Vividion’s technology is the most advanced in the industry, and it has demonstrated its ability to identify drug candidates that can target challenging proteins. Together with Bayer’s existing know-how, we will be able to develop first-in-class drug candidates, increasing the value of our pipeline. We want to provide innovative therapies for patients whose medical needs are not yet met by today’s treatment options.”

by Amanda Jasi

Source: thechemicalengineer.com

 

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).